GGrantIndex
← Search

CORE--TRANSGENIC MOUSE/EMBRYONIC STEM CELL

$167,178P30FY2002CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

Description: The UCLA Transgenic Mouse/Embryonic Stem (ES) Cell Shared Resource was established to accommodate individual investigator?s needs in the production of transgenic and knockout mice and to provide for rederivation of strains to create specific pathogen-free mice. Resource personnel serve as consultants to many different investigations providing information on specific transgenic animal models, the design and assembly of DNA constructs, and the development of new methods. Materials can also be provided to investigators who wish to perform projects in their own laboratories. There are two separate components of the resource: Transgenic Mouse and ES Cell Culture. The Transgenic Mouse Facility was established in 1991. Although not funded by NCI in the last competitive renewal application, the institution has subsidized the facility?s operation because access to transgenic and knockout technology plays a vital role in the Cancer Center?s research mission. The facility performs pronuclear injections of DNA and blastocyst injections of targeted ES cells, rederives mouse strains, and maintains transgenic animal lines in their initial stages. The Embryonic Stem Cell Facility is not yet operational. Institutional funds have been utilized to recruit a director, renovate space, and provide equipment for the facility. Once operational, a formal service for culture, electroporation, drug selection, and expansion of ES clones will be available. The measure of usage is based on injection days for the transgenic facility and targeting projects for the ES facility. The total capacity for the transgenic facility is 240 injection days and for the ES facility, 25 cell targeting projects. Twenty four UCLA faculty members used the resource representing assistance to 66 individual projects. Of these, use by peerreviewed Cancer Center members totaled 60 percent. The total operating budget of the shared resource for 1997-1998 is $259,672, with 25 percent requested, 50 percent to be obtained from AIDS chargebacks, and 25 percent from institutional support.

View original record on NIH RePORTER →